5 ESSENTIAL ELEMENTS FOR ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Segment A, contributors will acquire distinctive doses and schedules of oral ABBV-744 tablet to recognize Protected dosing program. Added individuals will probably be enrolled at the discovered monotherapy dosign routine. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C,